VivoSeq
Nephrology

Kidney Failure

40

Pipeline Programs↗

3

Active Trials↗

21

Companies Involved↗

Kidney Failure is a moderately active landscape with 40 programs across 21 companies. The most active players are Bayer, Novo Nordisk, Gilead. 19 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

6/100

Mech. Concentration

9/100

Completion Rate

42/100

Attrition Rate

35/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Roche logo

Roche

3 programs

Phase 3Pfizer logo

Pfizer

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

34 of 41 classified programs — the dominant modality here.

17%ALL OTHERSPeptide37%Vaccine25%Monoclonal antibody12%Protein / enzyme12%

Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 100% of 45 pipeline programs.

Analysis

Trial Status

17

clinical trials

Terminated5 · 29%
Completed5 · 29%
Not yet recruiting2 · 12%
Unknown status2 · 12%
Suspended1 · 6%
Active, not recruiting1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

17 trials

Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation
Active, not recruiting·—·Phase 3·NCT05568160·840 enrolled
Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure
Not yet recruiting·SShahid Beheshti University of Medical Sciences·N/A·NCT07176663·15 enrolled
IMPACT OF KIDNEY FAILURE ON THE REGULATION OF HUMORAL RESPONSE TO VACCINATION
Not yet recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·N/A·NCT06635525·146 enrolled
Safety of Sofosbuvir in People With Advanced Kidney Failure
Completed·SSanjay Gandhi Postgraduate Institute of Medical Sciences·Phase 3·NCT03883698·30 enrolled
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
Completed·DDynavax Technologies Corporation·Phase 1·NCT00426712·42 enrolled
Effects of Mesna on Homocysteine in Kidney Failure
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00524199·10 enrolled
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
Completed·Bayer logoBayer·Phase 2·NCT04523220·704 enrolled
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Completed·National Cancer Institute (NCI)·Phase 1·NCT00026169·69 enrolled
Effect of Cytokines on Growth of Children With Chronic Kidney Failure
Suspended·WWeill Medical College of Cornell University·Phase 4·NCT00194883·50 enrolled
Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure
Terminated·—·N/A·NCT02857556·10 enrolled
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.
Terminated·MMelbourne Health·N/A·NCT00256100·20 enrolled
Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
Terminated·SSt. Joseph's Healthcare Hamilton·N/A·NCT00186745·148 enrolled
Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery
Terminated·MMedical University of Gdansk·Phase 3·NCT00557219·60 enrolled
Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia
Terminated·—·Phase 2·NCT01481610·28 enrolled
The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure
Withdrawn·—·Phase 2·NCT02284230
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)